6ps0
From Proteopedia
(Difference between revisions)
| Line 1: | Line 1: | ||
| - | '''Unreleased structure''' | ||
| - | + | ==XFEL beta2 AR structure by ligand exchange from Alprenolol to Carazolol.== | |
| - | + | <StructureSection load='6ps0' size='340' side='right'caption='[[6ps0]], [[Resolution|resolution]] 3.40Å' scene=''> | |
| - | + | == Structural highlights == | |
| - | + | <table><tr><td colspan='2'>[[6ps0]] is a 1 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6PS0 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6PS0 FirstGlance]. <br> | |
| - | + | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=CAU:(2S)-1-(9H-CARBAZOL-4-YLOXY)-3-(ISOPROPYLAMINO)PROPAN-2-OL'>CAU</scene>, <scene name='pdbligand=CLR:CHOLESTEROL'>CLR</scene>, <scene name='pdbligand=OLA:OLEIC+ACID'>OLA</scene>, <scene name='pdbligand=OLC:(2R)-2,3-DIHYDROXYPROPYL+(9Z)-OCTADEC-9-ENOATE'>OLC</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |
| - | [[Category: | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6ps0 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6ps0 OCA], [http://pdbe.org/6ps0 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6ps0 RCSB], [http://www.ebi.ac.uk/pdbsum/6ps0 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6ps0 ProSAT]</span></td></tr> |
| + | </table> | ||
| + | == Function == | ||
| + | [[http://www.uniprot.org/uniprot/ADRB2_HUMAN ADRB2_HUMAN]] Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately 30-fold greater affinity than it does norepinephrine. | ||
| + | __TOC__ | ||
| + | </StructureSection> | ||
| + | [[Category: Large Structures]] | ||
| + | [[Category: Batyuk, A]] | ||
| + | [[Category: Cherezov, C]] | ||
| + | [[Category: Gati, C]] | ||
| + | [[Category: Han, G W]] | ||
| + | [[Category: Ishchenko, A]] | ||
| + | [[Category: Iwata, S]] | ||
| + | [[Category: Joti, Y]] | ||
| + | [[Category: Li, C]] | ||
| + | [[Category: Liu, W]] | ||
| + | [[Category: Moraes, I]] | ||
| + | [[Category: Nakane, T]] | ||
| + | [[Category: Nango, E]] | ||
| + | [[Category: Shiriaeva, A]] | ||
| + | [[Category: Stauch, B]] | ||
| + | [[Category: Tanaka, R]] | ||
| + | [[Category: Tono, K]] | ||
| + | [[Category: Weierstall, U]] | ||
| + | [[Category: Zatsepin, N A]] | ||
| + | [[Category: Alprenolol]] | ||
| + | [[Category: B2ar]] | ||
| + | [[Category: Beta2ar]] | ||
| + | [[Category: Carazolol]] | ||
| + | [[Category: Complex-lcp method]] | ||
| + | [[Category: Drug design]] | ||
| + | [[Category: Gpcr]] | ||
| + | [[Category: Lcp-sfx]] | ||
| + | [[Category: Ligand exchange]] | ||
| + | [[Category: Membrane protein]] | ||
| + | [[Category: Sbdd]] | ||
| + | [[Category: Xfel]] | ||
Revision as of 11:07, 13 November 2019
XFEL beta2 AR structure by ligand exchange from Alprenolol to Carazolol.
| |||||||||||
Categories: Large Structures | Batyuk, A | Cherezov, C | Gati, C | Han, G W | Ishchenko, A | Iwata, S | Joti, Y | Li, C | Liu, W | Moraes, I | Nakane, T | Nango, E | Shiriaeva, A | Stauch, B | Tanaka, R | Tono, K | Weierstall, U | Zatsepin, N A | Alprenolol | B2ar | Beta2ar | Carazolol | Complex-lcp method | Drug design | Gpcr | Lcp-sfx | Ligand exchange | Membrane protein | Sbdd | Xfel
